HPC
AKTS

HM Payson & Co’s Aktis Oncology AKTS Stock Holding History

HM Payson & Co’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39K Buy
+74
New +$1.52K ﹤0.01% 1041

Other funds holding AKTS

MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
SIC
Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

HM Payson & Co's AKTS Position: Q2 2026 in Review

HM Payson & Co opened a new position in Aktis Oncology (AKTS) in Q2 2026: 74 shares worth $2.39K. The stake represents ﹤0.01% of the portfolio and ranks #1041 among its holdings.

8 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • HM Payson & Co held 74 shares of Aktis Oncology worth $2.39K as of Q2 2026.
  • Aktis Oncology was a new HM Payson & Co position in Q2 2026.
  • Aktis Oncology made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #1041 holding.
  • 8 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.